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DRUG COMPOSITION CYTOTOXIC FOR 
PANCREATIC CANCER CELLS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a national phase application oflnterna-
tional Application No. PCT /US2009/06607 9, which was filed 
on 30 Nov. 2009, which claims priority to U.S. provisional 
application Ser. No. 61/118,792, which was filed on 1 Dec. 
2008, and to U.S. provisional application Ser. No. 61/249, 
307, which was filed on 7 Oct. 2009, each application of 
which is incorporated herein by reference in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The invention was made with government support under 
ROI CAI 06439 awarded by the National Institutes of Health. 
The government has certain rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to the field of drug develop-
ment and, more particularly, to a drug composition cytotoxic 
for pancreatic cancer cells. 
BACKGROUND OF THE INVENTION 
Pancreatic cancer is a lethal disease with a poor prognosis 
and a mortality rate nearly the same as the rate of incidence. 
Moreover, the disease remains poorly understood. Multiple 
signal transduction proteins are activated during pancreatic 
ductal cell carcinogenesis, some may be secondary events, 
while many others might have critical roles and collectively 
contribute to the maintenance and the progression of the 
disease and its responsiveness to therapy. One of the major 
molecular abnormalities is the overexpression and/or activa-
tion of the EGFR protein, which has an incidence of30-50% 
2 
disease progression, but also influence the drug responsive-
ness. Within the context of the concurrent activation of 
EGFR, Src and Stat3 in pancreatic cancer, the potential for 
cooperation between EGFR and Src kinases to induce aber-
rant Stat3 activation and to cooperate in support of the cancer 
phenotype is a reasonable model to propose. Knowledge of 
this functional relationship and the collective roles of the 
proteins in supporting pancreatic cancer can facilitate the 
design of effective, multiple-targeted therapy for disease. We 
10 provide evidence that EGFR and Src promote constitutive 
Stat3 activation, with a compensatory Stat3 activation mecha-
nism from Jaks, and together support the pancreatic cancer 
phenotype. Importantly, our study identifies that the concur-
rent inhibition of aberrant Stat3 and EGFR or Src is more 
15 effective in inducing antitumor cell response and pancreatic 
tumor regression in xenografts. 
20 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides a cytotoxic composition containing a drug 
combination targeting two or more functional elements in 
pancreatic cancer cells, the functional elements comprising 
EGFR or Src and Stat3 or Jaks. A preferred embodiment of 
25 the cytotoxic composition is one wherein the drug combina-
tion contained therein is selected from ZD and S3I-201, Das 
and S31-201, ZD andAG490, Das andAG490, and combi-
nations thereof. Furthermore, the preferred cytotoxic compo-
sition is that wherein the drug combination inhibits said func-
30 tional elements at substantially the same time. The preferred 
composition of the present invention may also comprise a 
nucleoside analog inhibitory for DNA replication, for 
example, Gemcitabine. 
The invention herein disclosed also includes a method of 
35 cytotoxically affecting (which could result in killing) pancre-
atic cancer cells, the method comprising contacting the cells 
with a drug combination which inhibits two or more cellular 
functional elements, the functional elements including EGFR 
of pancreatic cancer cases (1). Evidence indicates that the 40 
hyperactive EGF /EGFR duo is important in the disease main-
tenance and progression (2). Similarly, the overexpression of 
the c-Src tyrosine kinase occurs in a large percentage of 
pancreatic adenocarcinoma and is observed to augment 
EGFR activities during tumorigenesis (3, 4). The over-activ- 45 
ity of Src family kinases leads to deregulation of tumor cell 
growth and survival, disruption of cell-to-cell contacts, and 
the promotion of migration and invasiveness, and the induc-
tion of tumor angiogenesis (4, 5). 
or Src and Stat3 or Jaks. The method of the invention also 
includes an embodiment wherein the drug combination is 
selected from ZD and S31-201, Das and S31-201, ZD and 
AG490, Das and AG490, and combinations thereof. A pre-
ferred method of the invention also includes contacting the 
cells with a drug combination further comprising a nucleo-
side analog inhibitory for DNA replication, the nucleoside 
analog preferably being Gemcitabine. 
The invention additionally includes a method of making a 
therapeutic medication cytotoxic for pancreatic cancer cells, 
the method comprising preparing a pharmaceutically accept-
able composition containing a drug combination selected 
from ZD and S31-201, Das and S31-201, ZD andAG490, Das 
Another molecular abnormality is the aberrant activation 50 
ofStat3, a member of the Signal Transducer and Activator of 
Transcription (STAT) family of cytoplasmic transcription 
factors, which has also been detected in pancreatic tumors 
and tumor cell lines and been implicated in the disease (6-9). 
Stat3, as are the other STATs, requires extrinsic tyrosine 55 
phosphorylation to become activated and this is induced by 
growth factor receptors and cytoplasmic tyrosine kinases, 
such as Src and Janus kinase (Jaks) families (10). In contrast 
to normal STAT signaling that is transient in accordance with 
the requirements for normal biological processes, tumor cells 60 
harbor aberrant Stat3 activation. Studies show that aberrant 
and AG490, and combinations thereof. The method of mak-
ing the medication preferably also includes an embodiment 
wherein the drug combination further comprises a nucleoside 
analog inhibitory for DNA replication, for example, Gemcit-
abine. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings in which: 
Stat3 dysregulates cell growth and survival, promotes tumor 
angiogenesis, cell migration and invasion, and induces tumor 
immune tolerance (11-13). 
De-regulated signal transduction provides the framework 
for functional cooperativity and signaling cross-talk that 
would not only support the malignant phenotype and the 
FIG. 1 shows EMSA and immunoblotting analyses of 
65 Stat3, Src and EGFR activities for effects of inhibitors. (A) 
EMSA analysis of STAT DNA-binding activity using (i) 
high-affinity sis-inducible element (hSIE) probe that binds 
US 8,685,941 B2 
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Stat3 and Statl or (ii) mammary gland factor element (MG Fe) 
probe that binds Statl or Stat5; and (Band C) Immunoblot-
ting analysis ofwhole-cell lysates from cells (B) (i) untreated 
or (ii) treated with ZD 1839 (ZD), or Dasatinib (Das), or 
transfected with or without (iii) Src siRNA, (iv) EGFR 5 
siRNA, or scrambled siRNA control (con) and probing for 
pY416c-Src (pY416Src), Src, pY845EGFR, and EGFR; and 
(C) untreated or treated with ZD or Das and probing for (i) 
4 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, and other references mentioned herein are 
incorporated by reference in their entirety. In case of conflict, 
the present specification, including any definitions, will con-
trol. In addition, the materials, methods and examples given 
are illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
p YI 068EGFR, (ii) p YI 086EGFR and (iii) p YI I 73EGFR, 
and EGFR. Positions of STAT:DNA complexes in gel are 10 
shown; *Supershifts were performed with antibodies specifi-
cally recognizing either Statl (a-Statl), Stat3 (a-Stat3), or 
Stat5 (a-Stat5a or a-Stat5b); asterisk indicates position of 
supershifted complexes. Data are consistent with those 
obtained from 4 independent experiments. 15 ent forms and should not be construed as limited to the illus-
FIG. 2 depicts EMSA and immunoblotting analyses for 
effects of inhibitors on Stat3. (A and B) EMSA analysis of 
Stat3 DNA-binding activity in (A) Pane-I or (B) Colo-357 
cells treated or untreated with the pan ErbB inhibitor, 
PD169540 (PD169), ZD 1839 (ZD), Dasatinib (Das), the Jak 20 
inhibitor, AG490, the ErbB2-selective inhibitor, AG879, or 
inhibitor combinations for the indicated times, or (C) immu-
noblotting analysis of whole-cell lysates from Pane-I cells 
transfected with EGFR siRNA, Src siRNA, or scrambled 
siRNA (control) and probing for pStat3 or Stat3. *Supershift 25 
analysis. Data are consistent with those obtained from 3 inde-
pendent experiments. 
FIG. 3 presents data of cell viability studies for effects of 
inhibitors. (A and B) Trypan blue exclusion/phase-contrast 
microscopy for viable Pane-I or Colo-357 cells following 30 
treatment for 0-96-h inhibitor with I µM ZD, I 00 nM Das, 50 
µM S3 l-201, Jak inhibitor, AG490, or combinations; (C and 
D) CyQuant cell proliferation assay for viability of Pane-I (C, 
left panel, and D(i)) or Colo-357 cells (C, right panel and 
D(ii)) for effects of 48-h treatments with the designated con- 35 
centrations of ZD, Das, S3 l-201, Gemcitabine (Gem) alone 
and in combinations. Values, mean and S.D., n=4 experiments 
each in triplicates. p values, *-<0.05, **-<0.01, and ***-
<0.001. 
trated embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
Materials and Methods 
Cells and Reagents. 
v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), 
human pancreatic cancer (Pane-I) and leukemic (K562) lines 
have been described (14-16). The human pancreatic cancer 
lines, Colo-357 and Mia-PaCa-2 were kind gifts from Drs. 
Lancaster and Mokenge (Moffitt Cancer Center). The immor-
talized human pancreatic duct epithelial cell (HPDEC) line 
was obtained from Dr. Tsao, OCI, UHN-PMH, Toronto) (17). 
Except for HPDEC grown in Keratinocyte-SFM media 
supplemented with 0.2 ng EGF, 30 µg/mL bovine pituitary 
extract and containing antimycol, and K562 line in RPMI 
1640 containing I 0% heat-inactivated FBS and 100 units/ml 
penicillin-streptomycin, all other cell lines were grown in 
Dulbecco's modified Eagle's medium (DMEM) containing 
5% iron-supplemented bovine calf serum and I 00 units/ml 
penicillin-streptomycin. Recombinant human EGF (hEGF) is 
40 from Creative Biolabs, Port Jefferson Station, N.Y.); Gemcit-
abine is from Ely Lilly (Indianapolis, Ind.). 
FIG. 4 shows colony survival and apoptosis studies for 
effects of inhibitors. (A) Number of colonies emerging from 
cells in culture ( 500 per 6 cm dish) untreated or treated once 
with ZD1839 (ZD), Dasatinib (Das), S3I-201 (S3I), or com-
binations and allowed to culture; or (B) Annexin V binding/ 
Flow Cytometry analysis of normal HPDEC, Pane-I or Colo- 45 
357 cells treated or untreated with inhibitors or combinations. 
Values, mean and S.D., n=4 experiments each in triplicates. p 
values, *-<0.05, **-<0.01, and ***-<0.001. 
Nuclear Extract Preparation and Gel Shift Assays. 
Nuclear extract preparation and DNA-binding with elec-
trophoretic mobility shift assay (EMSA) were carried out, as 
previously reported (14, 15). The 32P-labeled oligonucleotide 
probes used were hSIE (high affinity sis-inducible element 
from the c-fos gene, m67 variant), 5'-AGCTTCATTTCCCG-
TAAATCCCTA; (SEQ ID NO: I) that binds Statl and Stat3 
50 
(Wagner et al., 1990) and the MGFe (mammary gland factor 
element from the bovine ~-casein gene promoter, 5'-AG-
ATTTCTAGGAATTCAA; (SEQ ID N0:2) that binds Statl 
and Stat5 (Gouilleux et al., 1995; Seidel et al., 1995). 
FIG. 5 presents the concurrent inhibition of Stat3 and 
EGFR or Src inhibits migration and invasion and suppresses 
c-Myc expression. (A) Effects of ZDl839 (ZD), Dasatinib 
(Das), and/or S3I-201 (S3I) on migration and invasion; (B) 
Immunoblotting analysis ofwhole-cell lysates for c-Myc and 
b-Actin expression in Pane-I cells. Values, mean and S.D., 
n=3-4 experiments each in triplicates. p values, *-<0.05, 55 
**-<0.01, and ***-<0.001. 
SDS-PAGE/Westem Blot Analysis. 
Western blotting analysis was performed as previously 
described (15, 18). Primary antibodies used were anti-Stat3 
(C20) (Santa Cruz, Santa Cruz, Calif.), anti-pY845EGFR 
(Upstate Biotech, Millipore, Billerica, Mass.), and antibodies 
against p Y705Stat3, Stat3, p YI 068EGFR, p YI 086EGFR, 
FIG. 6 is a line graph showing progression of tumor volume 
under the different therapies; concurrent inhibition of Stat3 
and EGFR or Src induces human pancreatic tumor growth 
inhibition in xenografts. 60 pY1173EGFR, EGFR, pY416Src, Src, c-Myc, and ~-Actin 
from Cell Signaling (Danvers, Mass.). 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The present invention will now be described more fully 65 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Inhibitors 
The inhibitors used herein are known to the art. 
ZD or ZDl839 (Iressa™) is also referred to as Gefitinib 
(CAS No. 184475-32-2). ZDl839 has the molecular formula 
C22H24ClFN4 0 3 . ZD has the formula: 
US 8,685,941 B2 
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See References 24 and 25. 
S3I-201 or S3I is also referred to as NSC 74859 (Cas No. 
501919-59-1). S3I has the molecular formula C16H15N07 S. 
S3I has the formula: 
0 0 
(Y~TI)Y~ 
HOYY 0 ~. 
0 OH 
See Reference 30. 
Das or Dasatinib (Sprycel™) is also referred to as BMS-
354825 (CAS No. 302962-49-8). Das has the molecular for-
mula C22H26ClN70 2 S. Das has the formula: 
See Reference 23, 29, and 35. 
AG490 is also referred to as TyrphostinAG490 (CAS No. 
133550-30-8). AG490 has the molecular formula 




See Reference 14. 
Small-Interfering RNA (siRNA) Transfection. 
siRNA sequences for EGFR and Src were ordered from 
Dharmacon RNAi Technologies, Thermo Scientific (Lafay-
ette, Colo.). Sequences used are: EGFR sense strand, 
5'-GAAGGAAACUGAAUUCAAAUU-3', SEQ ID N0:3; 
EGFR antisense strand, 5'-UUUGAAUUCAGUUUCCUU-
CUU-3, SEQ ID N0:4'; control siRNA sense strand, 
5'-AGUAAUACAACGGUAAAGAUU-3', SEQ ID N0:5; 
and control siRNA antisense strand, 5'-UCUUUACCGUU-
GUAUUACUUU-3', SEQ ID N0:6. The c-Src SMARTpool 
siRNA reagent (NM-005417, Catalog #M-003175-01-05) 
6 
was used for Src. Transfection into cells was performed using 
20 nM of EGFR siRNA or 25 nM of Src siRNA and 8 µl 
Lipofectamine RNAiMAX (Invitrogen Corporation, Carls-
bad, Calif.) in OPTI-MEM culture medium (GIBCO, Invit-
5 rogen). 
Cell Proliferation Viability Assay andAnnexin V Binding and 
Flow Cytometry. 
Proliferating cells in 6-well or 96-well plates were treated 
once with 0.1-1 mM ZD 1839 (Iressa) (reference 25), I 00 nM 
10 Dasatinib (references 23 and 35), 50-100 µM S3 l-201, I µM 
Gemcitabine (reference 43 ), or combinations of inhibitors for 
up to 96 h. Viable cells were counted by trypan blue exclu-
sion/phase contrast microscopy or assessed by CyQuant cell 
viability assay, according to manufacturer's (Invitrogen) 
15 instructions, or cells were processed for Annexin V binding 
(BD Biosciences) with flow cytometry for apoptosis. S31-
201 is fully described in reference 30 (see below). 
Colony Survival Assay. 
Single-cell suspension of Pane-I and Colo-357 cells were 
20 seeded in 6-cm dishes (500 cells per well) and assayed as 
previously reported (19), treated the next day with inhibitors 
for 48 h, and allowed to grow until large colonies were visible. 
Colonies were stained with crystal violet for 4 hand counted 
under phase-contrast microscope. 
25 Cell Migration and Matrigel Invasion Assays. 
Cell migration and invasion experiments were carried out and 
quantified as previously described (20), using Bio-Coat 
migration chambers (Becton Dickinson, Franklin, N.J.) of 
24-well companion plates with cell culture inserts containing 
30 8 µm pore size filters, according to the manufacturer's proto-
col. 
Statistical Analysis. 
Statistical analysis was performed on mean values using 
Prism GraphPad Software, Inc. (La Jolla, Calif.). The signifi-
35 cance of differences between groups was determined by 
paired t-test at p <0.05*, <0.01 **,and <0.001 ***. 
Results 
Aberrant EGFR, Src and Stat3 in Pancreatic Cancer Lines. 
Consistent with published reports ( 6, 7), Stat3 activity, per 
DNA-binding with EMSA analysis in nuclear extract prepa-
rations is constitutive in Pane-I and Colo-357, low in Mia-
Paca-2, and undetectable in the normal human pancreatic 
duct epithelial cells (HPDEC), compared to aberrant levels in 
NIH3T3/v-Src (15) (FIG. lA(i)). Per supershift analysis, the 
45 DNA-protein complex contains Stat3 (FIG. lA(i), lane 3). By 
contrasts, Stat5 activity is undetectable in pancreatic cancer 
cells (FIG. lA(ii)), compared to aberrant levels in the K562 
leukemic cells (16). 
EGFR and c-Src are aberrant in many human cancers (2, 4). 
50 Immunoblotting analysis showed a moderate pY416c-Src 
level in Mia-Paca-2, but enhanced levels in Pane-I and Colo-
357 cells similar to levels in NIH3T3/v-Src, compared to low 
levels in HPDEC (FIG. lB(i), upper panel). The elevated 
p Y 4 I 6Src levels parallel enhanced levels of the Src-sensitive 
55 p Y845EGFR motif (21) in Pane-I and Colo-357 cells, com-
pared to low levels of same in HPDEC (FIG. lB(i), lower 
panel). Total Src or EGFR protein remained unchanged. 
Immunoblotting analysis further showed elevated levels of 
the EGFR autophosphorylation motifs (22), pYI068EGFR 
60 (FIG. lC(i), lanes 2 and 7), pYI086EGFR (FIG. lC(ii), lanes 
2 and 7) and pYl I 73EGFR (FIG. lC(iii), lanes 2 and 7) in 
Pane-I and Colo-357, compared to basal levels of same in 
HPDEC (FIG. lC(i)-(iii), lane I). 
Functional Integration ofEGFR and Src in Pancreatic Cancer 
65 Cells. 
We next examined the functional relationship between the 
activated EGFR and Src. Immunoblotting analysis showed 
US 8,685,941 B2 
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treatment of cells with Dasatinib (Das) inhibited Src activity 
(pY4I6Src) (23) and induced an early (I h) and a sustained 
(24 h) decrease in p Y845EGFR levels (FIG. lB(ii)). By con-
trast, no detectable changes in pY4I6Src and pY845EGFR 
levels were induced by treatment with the pan-ErbB inhibitor, 5 
PD169540 (PD169) (24) (data not shown) or the selective 
EGFR inhibitor, ZD I839 (ZD, Iressa) (25) (FIG. lB(ii)). In 
confirmation, siRNA knockdown of c-Src abrogated 
pY845EGFR levels (FIG. lB(iii), Src siRNA), while EGFR 
knockdown by siRNA had minimal effect on p Y 4 I 6Src level 1 o 
(FIG. lB(iv), EGFR siRNA). Scrambled siRNA has no effect 
(FIG. lB(iii) and (iv), con siRNA). Thus, elevated 
p Y845EGFR levels in pancreatic cancer cells are sensitive to 
Src activity. 
Immunoblotting analysis further showed that treatment of 15 
Pane-I and Colo-357 cells with ZD diminished 
pYI I73EGFR levels (FIG. lC(iii), lanes 3, 4, 8 and 9) by as 
early as I h and up to 24 h, with no effect on p YI 068EGFR 
(/FIG. lC(i), lanes 3, 4, 8 and 9) orpYI086EGFR level (FIG. 
lC(ii), lanes 3, 4, 8 and 9), suggesting that EGFR kinase is 20 
essential for the induction of p YI I 73EGFR levels, but not 
8 
same in response to the stimulation of normal HPDEC 
(Supplemental FIG. Sl, lane 2), except for pYI068EGFR 
levels in Pane-I (FIG. Sl(ii), upper right panel). In control 
studies, immunoblotting analysis showed elevated pErkI/ 
pErk2MAPK and pAkt in Pane-I and Colo-357 cells com-
pared to normal HPDEC, neither of which was significantly 
affected by treatment with ZD or Das (data not shown). 
Inhibition of Stat3 Sensitizes Pancreatic Cancer Cells In Vitro 
to EGFR and Src Inhibitors. 
Given the preceding data on the inter-relation between 
EGFR, Src and Stat3 activation, we investigated the biologi-
cal implications and the therapeutic potential of a combina-
torial approach. Dasatinib and ZD were used at I 00 nM and 
O.I-I µM, respectively, as in literature reports (23, 24), while 
the Stat3 inhibitor, S3I-201 was used at the sub-optimum, 50 
µM, or at the I 00 µM required to inhibit Stat3 activation (30). 
Viable cell count by trypan blue exclusion/phase-contrast 
microscopy showed that treatment with I µM ZD, I 00 nM 
Das, or 50 µM S3I-20I alone minimally affected cell viability 
by 24 h (FIG. 3A Day I). By contrast, treatment for 48 to 96 
h with or Das or S3I-20I alone progressively decreased cell 
viability, while treatment forthe same period with ZD showed 
minimal effect (FIG. 3A), except at 96 h when the number of 
viable Pane-I cells decreased (FIG. 3A(i), ZD, Day 4). Com-
p YI 068EGFR or p YI 086EGFR. By contrast, Das treatment 
decreased pYI068EGFR and pYI086EGFR levels (FIG. 
lC(i) and (ii), lanes 5, 6, IO and I I), with minimal effect on 
pYEGFRI I 73 (FIG. lC(iii), lanes 5, 6, 10 and I I). 
Both EGFR and Src Promote Aberrant Stat3 Activation. 
25 paratively, the combined inhibition of Stat3 (by S3I-20I) and 
EGFR (by ZD) or Src (by Das) or the combined treatment 
with AG490 (Jaks inhibitor) and ZD or Das induced greater 
losses of viability at 48-96 h (FIGS. 3A and B). The effects on 
Both the p YI 068EGFR and p YI 086EGFR levels are bind-
ing sites for Stat3 (27, 28). Given the concurrent EGFR and 
Src activation in Pane-I and Colo-357 cells, we sought to 
define the regulation of aberrant Stat3 activation. By in vitro 30 
DNA-binding assay with EMSA analysis of nuclear extract 
preparations, we observe an early repression (in the first 30 
min to I h of treatment) of constitutively-active Stat3 by the 
pan-ErbB inhibitor, PD I 69540 (PD I 69), the ErbB2-selective 
inhibitor, AG879 (7), ZD, or Das (FIG. 2A(i), lanes 4, 5, 7, 35 
and 8, and (ii), lanes 2, 4, 6, and I I, and FIG. 2B, I h), or by 
a combined PD I 69 and Das (FIG. 2A(i ), lanes I 0 and I I, and 
(ii), lane 8). However, the Stat3 activity in Pane-I cells con-
sistently rebounded following 24 h treatments with Das, ZD, 
or PDl 69 (FIGS. 2A(i) and (ii), 24 h), even though EGFR or 40 
Src activity remained inhibited (FIGS. 1B and lC, 24 h). 
Twenty-four hour treatment with the AG879 moderately 
inhibited Stat3 activity (FIG. 2A(ii), lane I2), which we 
speculate may be due to its widespread activity as a pan-ErbB 
inhibitor. By contrast, treatment with the Jak inhibitor, 45 
AG490 for I h had no effect on constitutive Stat3 activity, but 
surprisingly abolished Stat3 activity at 24 h treatment (FIG. 
2A(ii), lanes 9 and IO). Moreover, combined treatment with 
AG490 and ZD, Das or PDI69 for 24 h similarly abolished 
constitutively-active Stat3 (FIG. 2A(ii), lanes I4, I5, and I6). 50 
In Colo-357, Stat3 activity was inhibited by both ZD and Das, 
with the effects more striking for Dasatinib (FIG. 2B). These 
findings together reveal a pattern of constitutive Stat3 activa-
tion in pancreatic cancer cells that is mediated by both EGFR 
and Src, and a compensatory, Jak-dependent secondary Stat3 55 
activity. A similar pattern of Stat3 activation has been 
observed in head and neck squamous carcinoma, mesothe-
lioma, squamous cell skin carcinoma, and non-small cell lung 
cancer cell lines following the inhibition of Src (29). In fur-
ther support, the siRNAknockdown ofEGFR (EGFR siRNA) 60 
or Src (Src siRNA) led to pStat3 suppression, as assayed by 
immunoblotting analysis (FIG. 2C). Scrambled siRNA (con) 
has no effect. Immunoblotting analysis also shows that EGF 
stimulation induces pY705Stat3, pYI086EGFR, 
pYII73EGFR, pY845EGFR and pY4I6c-Src (Supplemen- 65 
ta! FIG. Sl(i)-(iii), lane 4) over and above constitutive levels 
in Pane- I cells, in a manner that is similar to the induction of 
cell viability as captured by trypan blue exclusion were con-
firmed by the CyQuant cell proliferation/viability assay. 
Unlike 24 h treatment duration that showed minimal effect on 
viability (FIG. 3A), CyQuant assay showed that 48-h treat-
ment with each inhibitor alone decreased viable cell numbers 
(quantified as fluorescent unit, FU) in a dose-dependent man-
ner (FIG. 3C, ZD, Das andS3I-201). We infer from the graphs 
that treatment with I µM ZD for 48 h has minimal effect on 
cell viability (FIGS. 3C(i) and (iv)), as observed by the trypan 
blue exclusion assay (FIG. 3A). However, the observed 
effects of single agents were significantly weaker compared 
to the concurrent treatment with a Stat3 inhibitor and an 
inhibitor of EGFR or Src. Results show that the treatment 
with S3I-201 increased the sensitivity of Pane-I and Colo-
357 cells to ZD and Das, shifting the dose-response curves to 
the left (FIG. 3C, ZD+S3I-20I, and Das+S3I-20I). Concur-
rent treatment with S3I-20I significantly decreased the IC50 
values as follows: I 7to 0.4 µM, and IOOto 6 nM, respectively, 
for ZD and Das against Pane-I viability (FIG. 3C(i) and (ii)); 
and 6.5 to 2.4 µM, and 90 to 8 nM, respectively for ZD and 
Das againstColo-357 viability (FIGS. 3C(iv) and(v)). For the 
impact of ZD and Das on the sensitivity to S3I-20I, CyQuant 
cell viability assay showed that Das, but not ZD increased the 
sensitivity of both cell lines to S3I-20I, decreasing its IC50 
from 40 to I5 µM, and from 45 to 20 µM, respectively, for 
effects on Pane-I and Colo-357 cells (FIGS. 3C(iii) and (iv)). 
Thus, treatment with S3I-20I sensitized cells to ZD and Das, 
while treatment with Das, but not ZD similarly sensitized 
cells to S3I-201. 
Given the clinical implications of these findings, we 
extended these studies to examine the effect ofEGFR Src and 
Stat3 pathway on the response to Gemcitabine, the anti-me-
tabolite agent used in the treatment of pancreatic cancer. 
CyQuant cell proliferation/viability studies showed that inhi-
bition ofEGFR, Src or Stat3 sensitized Pane-I and Colo-357 
cells to Gemcitabine (FIG. 3D). More importantly, the com-
bined inhibition of Stat3 and EGFR or Src induced a higher 
sensitization of cells to Gemcitabine than that induced by the 
inhibition of any one alone (FIG. 3D). 
US 8,685,941 B2 
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As known to the skilled, Gemcitabine is a nucleoside ana-
log of cytidine which interferes with DNA replication, arrest-
ing tumor growth and resulting in apoptosis of the cell. Gem-
citabine is also known to bind to the active site of the enzyme 
ribonucleotide reductase (RNR) to irreversibly inactive the 
enzyme, thus interfering with the cell's ability to produce 
deoxyribonucleotides necessary for DNA replication and 
repair. This also leads to apoptosis. As noted above, the com-
bined inhibition of Stat3 and EGFR or Src induces a higher 
sensitization of cells to Gemcitabine, creating another possi- 10 
bility for combination therapy of tumors. 
To further explore the sensitization potential of inhibition 
10 
and to evaluate the in vivo antitumor effects of concurrent 
inhibition of Stat3 and EGFR or Src. Data showed that in 
general, xenografts ofColo-357 cells showed low responsive-
ness to treatment with inhibitor ofEGFR, Src or Stat3 alone, 
although, as the therapy progressed, those tumors treated with 
only one inhibitor alone appeared to show reduced growth, 
which was statistically not significant from the control, non-
treated tumors (FIG. 6). By contrast, tumors from mice 
treated with combined S3I-201 and Das or S3I-201 and ZD 
consistently showed reduced growth and smaller tumor sizes 
throughout the entire study (FIG. 6). Thus, the residual tumor 
volumes (sizes) for tumors in mice treated with combination 
inhibitors were significantly different (p<0.05) from tumor 
volumes for tumors in control mice at days 20 and upwards 
post treatment. These in vivo antitumor effects of combina-
tion treatment with inhibitors ofS3I-201 and Das or S3I-201 
and ZD are consistent with the in vitro antitumor cell data and 
together indicate that aberrant Stat3 cooperates with hyper-
active EGFR or Src to sustain human pancreatic cancer. 
Discussion 
Within the context of aberrations in the EGFR, Src and 
Stat3 pathway in pancreatic cancer, present study reveals a 
strong role for Src in supporting aberrant EGFR activation by 
not only inducing the phosphorylation ofY845EGFR motif 
of aberrant Stat3, we performed colony survival assay (19). 
Results show that inhibition of Src (by Das) or Stat3 (by 
S3I-201 (S3I)), but not EGFR inhibition (by ZD) resulted in 15 
reduced colony numbers (FIG. 4A). More importantly, the 
concurrent inhibition of Stat3 and EGFR or Src resulted in 
much lower colony numbers (FIG. 4A), consistent with the 
much greater loss of viable cells due to the combined inhibi-
tion of Stat3 and EGFR or Src (FIG. 3). To extend these 20 
studies, we performed Annexin V binding/Flow Cytometric 
analysis for apoptosis. Higher percentages of Pane- I and 
Colo-357 cells undergoing apoptosis were observed for con-
current inhibition of Stat3 and EGFR or Src than for the 
inhibition any one signaling molecule alone (FIG. 4B(ii) and 
(iii)). Similar results were obtained for the concurrent treat-
ments withAG490 and ZD or Das (FIG. 4B(ii) and (iii)). By 
contrast, similar treatments of normal HPDECs showed no 
significant apoptosis (FIG. 4B(i)) with the combination treat-
ments. Thus, we establish that pancreatic cancer cells have 30 
higher sensitivity to concurrent inhibition ofStat3 and EGFR 
25 (31 ), but also promoting the induction of p YI 068EGFR and 
pYI086EGFR motifs. These Src-promoted events will 
greatly influence the status of EGFR in pancreatic cancer 
cells. A role for EGFR in aberrant Stat3 activation in cancer 
or Src than to the inhibition of a single entity. 
EGFR, Src and Stat3 Together Promote Pancreatic Cancer 
Cell Migration and Invasion. 
Aberrantly-active Src and Stat3 have both been implicated 35 
in tumor cell motility, migration, invasion and metastasis ( 4, 
23). in vitro matrigel assay confirmed that inhibition ofSrc or 
Stat3 alone suppresses migration and invasion (FIG. SA). 
However, concurrent inhibition of Stat3 and EGFR or Src for 
24-h has a stronger effect on Colo-357 migration and Pane-I 40 
invasion, except for Src inhibition, which showed a similar 
effect on Pane-I migration (FIG. SA). At the 24-h treatment 
when these studies were done, there is no significant effect on 
cell viability (FIG. 3). These findings are further evidence that 
pancreatic cancer lines are more sensitive to concurrent inhi- 45 
bition of Stat3 and Src or EGFR. 
EGFR, Src and Stat3 Module Regulates c-Myc Over-Expres-
sion in Pancreatic Cancer Cells. 
cells has previously been reported in other tumor cells, 
including head and neck squamous cell carcinoma and breast 
cancer (26, 32). Present study extends those findings to pan-
creatic cancer and show that EGFR is key in facilitating 
aberrant Stat3 activation. Moreover, the p YI 068EGFR and 
pYI086EGFR induction by Src is likely to have significant 
impact on the activation of Stat3, given that these two motifs 
are essential sites for the binding of Stat3 to EGFR in order to 
promote its phosphorylation and activation (27, 28). Further-
more, Src may not only facilitate Stat3 activation via the 
induction of those two Tyr motifs of EGFR, but it can also 
directly phosphorylate Stat3, as has been previously reported 
in other systems (18). It is therefore consistent that both 
hyperactive EGFR and Src promote baseline constitutive 
Stat3 activation in pancreatic cancer, as revealed by our study. 
The present study is also in agreement with an earlier report 
of ErbB-2-dependent constitutive Stat3 activation in Mia-
Paca-2 and UK Pan-I cells (7) and another study that showed 
that the full induction of Stat3 activation by ErbB2 required 
both Src and Jaks (33). Our findings indicate that Jaks con-
tribute to the maintenance of constitutive activation in reveal-
50 ing a Jak-dependent compensatory mechanism of Stat3 acti-
vation upon inhibition of EGFR and Src. Given that Jaks 
inhibition did not abolish aberrant Stat3 at the earliest time 
point, we deduce that this family of cytoplasmic tyrosine 
For insight into the underlying molecular mechanisms by 
which the EGFR, Src and Stat3 pathway may support the 
cancer phenotype, we studied the regulation of key cancer-
relevant genes. We show that c-Myc is over-expressed in 
pancreatic cancer lines compared to normal HPDEC (FIG. 
SB). Furthermore, the concurrent inhibition of Stat3 and 
EGFR or Src consistently repressed c-Myc expression. These 55 
findings suggest a functional synergy between EGFR, Src and 
Stat3 in inducing c-Myc expression in the context of pancre-
atic cancer phenotype and that the stronger repression of 
c-Myc expression contributes to the antitumor cell effects of 
and the increased sensitivity of pancreatic cancer lines to 60 
concurrent Stat3 and EGFR or Src inhibition. 
Inhibition of Tumor Growth by Combination Treatment 
Concurrent inhibition of Stat3 and EGFR or Src induces 
human pancreatic tumor growth inhibition in xenografts. 
Subcutaneous xenografts of Colo-357, a metastatic pancre- 65 
atic adenocarcinoma line were used to study the therapeutic 
implication of the Stat3, EGFR and Src inter-relationships 
kinases may not be the predominant mediators of the baseline 
aberrant Stat3. Thus, in pancreatic cancer cells, a two-phase 
model of activation of Stat3 signaling emerges composed of 
an EGFR- and Src-dependent baseline, constitutive Stat3 
induction, and an induced Stat3 activation that is dependent 
on Jaks. The observed secondary induction ofStat3 activation 
via Jaks has similarly been reported in head and neck squa-
mous cell carcinoma line (29) and could be due to growth-
stimulatory factors released from tumor cells (34), which in 
turn would induce the activation of Jaks and thereby promote 
Stat3 activation. 
EGFR, Src and Stat3 has each independently been estab-
lished to have critical roles in malignant transformation (6, 
14, 23, 26, 35), while their collective roles in promoting 
US 8,685,941 B2 
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tumorigenesis have not been explored. While the inhibition of 
the activity of each of the three proteins induced antitumor 
cell response to some degree, data presented here strongly 
indicate that the multiple targeting of Stat3 and EGFR or Src 
together has a higher potential to inhibit growth, viability, 5 
survival, malignant transformation, and migration and inva-
sion in vitro. 
12 
4. Trevion J G, Summy J M, Lesslie D P, et al. Inhibition of 
SRC expression and activity inhibits tumor progression 
and metastasis of human pancreatic adenocarcinoma cells 
in an orthotopic nude mouse model. Am J Pathol 2006; 
168:962-72. 
5. Parsons J T, Parsons S J. Src family protein tyrosine 
kinases: cooperating with growth factor and adhesion sig-
naling pathways. Curr Opin Cell Biol 1997; 9:187-92. Significantly, hyperactivation of the EGFR signaling has 
been deemed a prognostic indicator of low survival among 
pancreatic cancer patients (36-38). Also, there is evidence to 
indicate that the concurrence with aberrant Src signaling 
potentiates the effects of aberrant EGFR and induces biologi-
6. Scholz ASH, Detjen KM, Peters M, et al. Activated signal 
10 transducer and activator of transcription 3 (STAT3) sup-
ports the malignant phenotype ofhuman pancreatic cancer. 
Gastroenterology 2003; 125:891-905. 
cal synergy (3, 21, 39). Given the potential collective roles of 
Stat3, EGFR and Src in promoting and supporting pancreatic 
15 
cancer, the inhibition of any single entity alone is unlikely to 
be insufficient to impact the disease. Present data that simul-
taneous inhibition of Stat3 and EGFR or Src induced greater 
antitumor cell effects and a higher sensitization to Gemcitab-
ine provides a strong support for the opinion that Stat3 may 20 
cooperate with EGFR and Src to support the malignant phe-
notype. Indeed, the inhibition of Stat3 seemed to sensitize 
pancreatic cancer cells to the antitumor cell effects of ZD and 
Das. Multiple targeting of Stat3 and EGFR or Src therefore 
has the potential to induce a greater anti tumor efficacy. This is 25 
supported by our present data that concurrent treatment with 
theStat3 inhibitor, S3I-201 and ZD or Das induced greater 
regression of xenografts of Colo-357 than treatment with 
either inhibitor alone. Such a multiple-targeted therapy has 
received a strong interest in recent times, particularly given 30 
the dismal results in certain cases of molecular targeted 
monotherapy, such as anti-EGFR monotherapy (40, 41). 
Thus, a combined Gemcitabine and Erlotinib (EGFR TK 
inhibitor) therapy has recently been approved for patients 
with locally advanced/metastatic pancreatic cancer ( 42, 43), 35 
although we note by our data that the inhibition of Stat3 and 
EGFR or Src together induces a higher Gemcitabine sensi-
tivity than inhibition ofEGFR alone. The enhanced anti tumor 
effects due combined Stat3 and EGFR or Src inhibitors may 
7. DeArmond D, Brattain M G, Jessup J M, et al. Autocrine-
mediated ErbB-2 kinase activation of STAT3 is required 
for growth factor independence of pancreatic cancer cell 
lines. Oncogene 2003; 22:7781-95. 
8. Trevino JG, Gray M J, Nawrocki ST, et al. Src activation 
of Stat3 is an independent requirement from NF-kappaB 
activation for constitutive IL-8 expression in human pan-
creatic adenocarcinoma cells. Angiogenesis 2006; 9:101-
10. 
9. Toyonaga T, Nakano K, Nagano M, et al. Blockade of 
constitutively activated Janus kinase/signal transducer and 
activator of transcription-3 pathway inhibits growth of 
human pancreatic cancer. Cancer Lett 2003; 201:107-16. 
10. Darnell J E. Validating Stat3 in cancer therapy. Nat Med 
2005; 11:595-6. 
11. Yu H, Jove R. The STATS of Cancer-New molecular 
targets come of age. Nat Rev Cancer 2004; 4:97-105. 
12. Turkson J. STAT proteins as novel targets for cancer drug 
discovery. Expert Opin Ther Targets 2004; 8:409-22. 
13. Yue P, Turkson J. Targeting STAT3 in cancer: how suc-
cessful are we? Expert Opin Investig Drugs 2009; 18:45-
56. 
14. Garcia R, Bowman TL, Niu G, et al. Constitutive activa-
tion of Stat3 by the Src and JAK tyrosine kinases partici-
pates in growth regulation of human breast carcinoma 
cells. Oncogene 2001; 20:2499-513. 
15. Turkson J, Bowman T, Garcia R, Caldenhoven E, De 
Groot R P, Jove R. Stat3 activation by Src induces specific 
gene regulation and is required for cell transformation. Mo! 
Cell Biol 1998; 18:2545-52. 
in part be due stronger repression of the expression of c-Myc 40 
oncogene. Altogether, present study provides support for a 
multiple-modality therapeutic approach and lays the founda-
tion for concurrent targeting of aberrant Stat3 and EGFR or 
Src as a more effective approach for achieving an enhanced 
antitumor therapeutic efficacy in pancreatic cancer. 45 16. Huang M, Dorsey J F, Epling-Burnette PK, et al. Inhibi-
tion of Ber-Ab! kinase activity by PD180970 blocks con-
stitutive activation of Stat5 and growth of CML cells. 
Oncogene 2002; 21:8804-16. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider- 50 
17. Ouyang H, Mou L J, Luk C, et al. Immortal human 
pancreatic duct epithelial cell lines with near normal geno-
type and phenotype. Am J Pathol 2000; 157:1623-31. able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
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That which is claimed: 
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S3I-201, ZD andAG490, and Das andAG490. 
4. The method of claim 3, wherein two or more functional 
elements in pancreatic cancer cells comprise one ofEGFR or 
Src and one ofStat3 or Jaks. 
5. The method of claim 3, wherein the pharmaceutical 
composition further comprises gemcitabine. 
6. The method of claim 3, 
wherein the drug combination is ZD and S31-201 and the 
two or more functional elements in pancreatic cancer 
cells comprise EGFR and Stat3, 
wherein the drug combination is Das and S31-201 and the 
two or more functional elements in pancreatic cells com-
prise Src and Stat3; 
wherein the drug combination is ZD and AG490 and the 
two or more functional elements in pancreatic cancer 
cells comprise EGFR and Jaks, or 
wherein the drug combination is Das and AG490 and the 
two or more functional elements in pancreatic cancer 
cells comprise Src and Jaks. 
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8. The method of claim 3, wherein the pharmaceutical 
composition further comprises a pharmaceutically accept-
able carrier. 
9. A method of making a pharmaceutical composition, 
comprising: 
mixing a pharmaceutically acceptable carrier and a drug 
combination selected from ZD and S3I-201, Das and 
S3I-201, ZD andAG490, and Das andAG490. 
10. The method of claim 9, wherein the pharmaceutical 
composition further comprises gemcitabine. 
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